Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Sells $10,308.06 in Stock

Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff sold 12,726 shares of Seres Therapeutics stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $0.81, for a total value of $10,308.06. Following the sale, the chief executive officer now directly owns 192,039 shares of the company’s stock, valued at approximately $155,551.59. This trade represents a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Seres Therapeutics Price Performance

NASDAQ MCRB opened at $0.80 on Friday. The stock’s 50-day moving average is $0.84 and its 200-day moving average is $0.85. Seres Therapeutics, Inc. has a one year low of $0.54 and a one year high of $1.53. The firm has a market cap of $137.19 million, a P/E ratio of -3.49 and a beta of 2.11.

Analysts Set New Price Targets

A number of brokerages have issued reports on MCRB. Canaccord Genuity Group restated a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. Chardan Capital restated a “buy” rating and set a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. Finally, StockNews.com upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.08.

Institutional Trading of Seres Therapeutics

Several hedge funds have recently bought and sold shares of the stock. FMR LLC increased its position in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after acquiring an additional 140,096 shares in the last quarter. Millennium Management LLC increased its holdings in Seres Therapeutics by 77.2% during the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock worth $1,505,000 after purchasing an additional 788,762 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Seres Therapeutics by 8.8% in the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock valued at $1,256,000 after purchasing an additional 121,793 shares during the period. Vontobel Holding Ltd. lifted its holdings in shares of Seres Therapeutics by 137.6% in the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after purchasing an additional 543,469 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Seres Therapeutics by 15.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 117,107 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.